European registration of medicines: Pros and cons for prescriber and patient;Het Europees registreren van geneesmiddelen; consequenties voor voorschrijver en patient

Nederlands Tijdschrift voor Geneeskunde

Volumn 141, Issue 21, 1997, Pages 1028-1033

  Offerhaus, L ^a  

^a NONE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG APPROVAL; EUROPE; PRESCRIPTION; SHORT SURVEY;

EID: 0031001026     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (12)

1. Cartwright AC, Matthews BR, editors. Pharmaceutical product licensing - requirements for Europe. New York: Ellis Horwood, 1991.
2. Charlesworth F. The regulation of medicines in Europe. In: Mann RD, Rawlins MD, Auty RM, editors. A textbook of pharmaceutical medicine - current practice. Carnforth: Parthenon, 1993:259-68.
3. Giesen WF van der. Regulering van het geneesmiddelenaanbod. In: Buurma H, Jong-van den Berg LTW de, Leufkens HGM, redacteuren. Het geneesmiddel. Utrecht: Bunge, 1996:43-75.
4. Jefferys DB, Jones KH. EMEA and the new pharmaceutical procedures for Europe. European Medicines Evaluation Agency. Eur J Clin Pharmacol 1995;47:471-6.
5. European medicines evaluation agency and the new licensing arrangements. Drug Ther Bull 1994;32:89-90.
6. Aronson JK. Advantages and pitfalls of surrogate markers. In: Collier J, editor. From trial outcomes to clinical practice. Proceedings 4th symposium. Drug Ther Bull 1996;Suppl:5-10.
7. Koopmans PP. Registration of drugs for treating cancer and HIV infection: a plea to carry out phase 3 trials before admission to the market. BMJ 1995;310:1305-6.
8. Euromedicines evaluation: the striptease begins. Lancet 1996;347:483.
9. Herxheimer A. The European Medicines Evaluation Agency. BMJ 1996;312:394.
10. Herxheimer A. The rights of the patient in clinical research. Lancet 1988;ii:1128-30.
11. McNamee D. Speaking about pharmacovigilance. Lancet 1996;348:908.
12. The International Working Group. Statement of the International Working Group on Transparency and Accountability in Drug Regulation. Uppsala: Health Action International en Dag Hammarskjöld Foundation, 1996.